667 related articles for article (PubMed ID: 8722359)
21. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
[TBL] [Abstract][Full Text] [Related]
22. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
24. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
25. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
[TBL] [Abstract][Full Text] [Related]
26. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
[TBL] [Abstract][Full Text] [Related]
27. [Polymerase chain reaction in diagnosis of cytomegalovirus infection in patients with organ allotransplants].
Vediakov AM; Dolgikh MS
Ter Arkh; 1998; 70(4):45-8. PubMed ID: 9612903
[TBL] [Abstract][Full Text] [Related]
28. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
29. Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Boivin G; Handfield J; Toma E; Lalonde R; Bergeron MG
J Infect Dis; 1999 May; 179(5):1101-7. PubMed ID: 10191210
[TBL] [Abstract][Full Text] [Related]
30. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients.
Vlieger AM; Boland GJ; Jiwa NM; de Weger RA; Willemze R; de Gast GC; Falkenburg JH
Bone Marrow Transplant; 1992 Apr; 9(4):247-53. PubMed ID: 1318141
[TBL] [Abstract][Full Text] [Related]
33. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
34. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy.
Avery RK; Adal KA; Longworth DL; Bolwell BJ
Bone Marrow Transplant; 2000 Oct; 26(7):763-7. PubMed ID: 11042658
[TBL] [Abstract][Full Text] [Related]
35. Rapid detection cytomegalovirus pneumonia in recipients of bone marrow transplant: evaluation and comparison of five survey methods for bronchoalveolar lavage fluid.
Goto H; Yuasa K; Sakamaki H; Nakata K; Komuro I; Iguchi M; Okamura T; Ieki R; Tanikawa S; Akiyama H; Onozawa Y; Mochida Y
Bone Marrow Transplant; 1996 May; 17(5):855-60. PubMed ID: 8733709
[TBL] [Abstract][Full Text] [Related]
36. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
37. High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.
Butt NM; Clark RE
Bone Marrow Transplant; 2001 Mar; 27(6):615-9. PubMed ID: 11319591
[TBL] [Abstract][Full Text] [Related]
38. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: comparison with end-point PCR and pp65 antigen test.
Allice T; Enrietto M; Pittaluga F; Varetto S; Franchello A; Marchiaro G; Ghisetti V
J Med Virol; 2006 Jul; 78(7):915-22. PubMed ID: 16721848
[TBL] [Abstract][Full Text] [Related]
40. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
